2026 Gastric Cancer Treatment Drug Guide: Latest Dual-Target Therapies, 12 Approved Treatments, and 5 Emerging Technologies
Since the beginning of 2026, the field of gastric cancer treatment has witnessed a major…
Articles
China Innovative Drug Approvals April 2026: 6 Approved, 5 by Chinese Companies
April 2026 marked another milestone for China innovative drug approvals April 2026, as the country…
Drug Shortages by Country Causes and Supply Chain Solutions
From emergency medicines to chronic disease treatments, from anti-infectives to oncology therapies, instability in the…
Generic Upadacitinib Approved in China, Marking the Start of JAK Inhibitor Competition
On April 27, 2026, the National Medical Products Administration (NMPA) announced that Jiangsu Huayang Pharmaceutical’s…
Approved Immune Checkpoint Inhibitors in China: PD-1, PD-L1, CTLA-4 and Bispecific Antibodies
Immune checkpoint inhibitors (ICIs) restore T-cell–mediated antitumor immunity by blocking key regulatory pathways such as…
Belantamab Mafodotin Approved in China for Multiple Myeloma: First-in-Class BCMA ADC Marks New Milestone
On April 17, China’s National Medical Products Administration (NMPA) approved belantamab mafodotin in combination with…
Top 5 Global Neuroscience Pharma Companies: Core Products and Pipeline Analysis
Neuroscience (CNS) has long been regarded as one of the most challenging areas in the…
Sevabertinib Approved in China for HER2-Mutant NSCLC: A New Oral Targeted Therapy Option
On April 15, Bayer announced that its innovative targeted therapy Hyrnuo® (sevabertinib, BAY 2927088) has…
HCC First- and Second-Line Treatment Updates: What’s New in Current Guidelines
To further improve the standardization of diagnosis and treatment for primary liver cancer, the newly…
What Are the Top 5 Autoimmune Diseases to Watch in 2026? Insights into Immunotherapy Trends and Innovation
Over the past decade, autoimmune diseases have remained one of the most stable and high-growth…